252561-81-2

Basic information

• Product Name: 2-Chloro-4-bromoacetophenone
• Synonyms: 2-CHLORO-4-BROMOACETOPHENONE 99+%;1-(4-bromo-2-chlorophenyl)ethanone;4'-Bromo-2'-chloroacetophenone;4-Bromo-6-chloroacetophenone
• CAS NO: 252561-81-2
• Molecular Formula: C₈H₆BrClO
• Molecular Weight: 233.5
• Product Categories: Adehydes, Acetals & Ketones;Bromine Compounds;Chlorine Compounds
• Mol File: 252561-81-2.mol

Chemical Properties

• Boiling Point: 265.602 °C at 760 mmHg
• Flash Point: 114.433 °C
• Appearance: /
• Density: 1.566 g/cm³
• Vapor Pressure: 0.009mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-Chloro-4-bromoacetophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-4-bromoacetophenone(252561-81-2)
• EPA Substance Registry System: 2-Chloro-4-bromoacetophenone(252561-81-2)

Safety Data

• Hazard Codes: Xn
• Hazardous Substances Data: 252561-81-2(Hazardous Substances Data)

Usage

Uses

2''-Chloro-4''-bromoacetophenone

InChI:InChI=1/C8H6BrClO/c1-5(11)7-3-2-6(9)4-8(7)10/h2-4H,1H3

Upstream product

• 625446-26-6 4-Bromo-2-chloro-thiobenzoic acid S-pyridin-2-yl ester 
• 75-16-1 methylmagnesium bromide 
• 875306-64-2 4-bromo-2-chloro-N-methoxy-N-methylbenzamide 
• 59748-90-2 4-Bromo-2-chloro-benzoic Acid 
• 158435-41-7 4-bromo-2-chlorobenzaldehyde 
• 1002309-96-7 1-(4-bromo-2-chlorophenyl)ethan-1-ol 

Downstream Products

• 749927-98-8 3-(4-Acetyl-3-chloro-phenyl)-1-cyclopentyl-propan-1-one 
• 625446-27-7 2-(4-Bromo-2-chloro-phenyl)-2-methyl-[1,3]dioxolane 
• 943152-94-1 1-(4-bromo-2-chloro-phenyl)-ethylamine hydrochloride 
• 943152-99-6 1-(4-bromo-2-chlorophenyl)ethan-1-amine 
• 1002309-96-7 1-(4-bromo-2-chlorophenyl)ethan-1-ol 
• 1134915-38-0 3-(4-bromo-2-chloro-phenyl)-1,1,1-trifluoro-2-(2-methyl-pyridin-4-yl)-butan-2-ol 
• 1159186-41-0 5-(4-bromo-2-chlorophenyl)-1-methyl-1H-pyrazole 
• 1246383-18-5 5-[2-(4-bromo-2-chloro-phenyl)-1-hydroxy-propyl]-3-methyl-thiophene-2-carbonitrile 
• 1246685-10-8 2-(4-bromo-2-chloro-phenyl)-propionaldehyde 
• 1612165-61-3 2-[2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-(1,2,4-triazol-1-yl)pent-3-yn-2-ol 
• 1261613-32-4 1-(4-bromo-2-chloro-phenyl)-2-chloro-ethanone 
• 1612165-57-7 2-(4-bromo-2-chloro-phenyl)-1-chloro-pent-3-yn-2-ol 
• 1612165-59-9 2-(4-bromo-2-chloro-phenyl)-1-(1,2,4-triazol-1-yl)pent-3-yn-2-ol 

Relevant articles and documents

INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

2- PYRIDONE COMPOUND

PROBLEM TO BE SOLVED: To provide a compound that has excellent glucokinase (GK) activating action and is useful as a pharmaceutical. SOLUTION: The present invention provides a 2-pyridone compound represented by formula [1], and a tautomer or stereoisomer of the compound, or their pharmacologically acceptable salts, or their solvates (where R1 is RA-ZA-; RA is any of a carboxy group, a sulfo group or formula [5]). COPYRIGHT: (C)2016,JPOandINPIT

NEW PESTICIDAL COMPOUNDS AND USES

The invention relates to the use of known and novel phenalkyl carboxamide derivatives of the formula (I) wherein the structural elements have the meaning as indicated in the description, for the control of nematodes and/or other helminths, particularly in agriculture and in the animal health field, formulations containing such compounds, particularly agrochemical formulations, and methods for the control of nematodes and helminths. The invention further relates to novel phenalkyl carboxamide derivatives, processes for their preparation, formulations containing such compounds, methods for the control of nematodes and helminths and their use as pest controlling agents, particularly their use as nematicides and their use as anthelmintics against endoparasites in animals and humans.

SUBSTITUTED HYDANTOINS

The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.

NITROGEN-CONTAINING HETEROCYCLYL KETONES AND METHODS OF USE

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

NOVEL FUSED IMIDAZOLE DERIVATIVE

The present invention relates to a compound represented by the Formula [I]: Wherein: the A ring is a 5-membered aromatic heterocyclic group containing at least one hetero atom selected from a nitrogen atom, and the like; A1 and A2, are each a nitrogen atom, and the like; X2, X3, X4, and X5 are all carbon atoms, or alternatively any one of X2, X3, X4, and X5 is a nitrogen atom and the rest are all carbon atoms; R1 is a hydrogen atom, or the like; R2, R3, R4, and R5, are each a hydrogen atom, or the like; R6 and R6', are each a hydrogen atom, and the like; R7 is an aryl group and the like; and R8 is an amino group or a hydroxy group, or a pharmaceutically acceptable salt or ester thereof.

Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same

The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

Compounds of formula (I) are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus.